Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–12 of 12 results
Advanced filters: Author: Yael P Mosse Clear advanced filters

  • The native anaplastic lymphoma kinase (ALK) oncofetal protein is expressed in neuroblastoma and in multiple pediatric and adult solid tumors. Here, the authors show an ALK-directed antibody-drug conjugate with therapeutic efficacy in ALK-expressing preclinical models.

    • Alberto D. Guerra
    • Smita Matkar
    • Yael P. Mossé
    ResearchOpen Access
    Nature Communications
    Volume: 16, P: 1-16

  • Inhibition of ALK is initially effective in patients with ALK-driven lung cancer but resistance often arises. Here, the authors use circulating tumour DNA, collected as part of a phase I trial investigating lorlatinib (ALK inhibitor) in pediatric patients with ALK-driven neuroblastoma, to detect early resistance mechanisms.

    • Esther R. Berko
    • Gabriela M. Witek
    • Yaël P. Mossé
    ResearchOpen Access
    Nature Communications
    Volume: 14, P: 1-13

  • Neuroblastoma is a debilitating disease and a leading cause of childhood cancer deaths. The discovery of ALK as a mutated oncogenic receptor in neuroblastoma has provided an attractive target for innovative therapies. In this article, Mosse and Carpenter review the preclinical and clinical advances in ALK-targeted therapies for neuroblastoma and discuss the emerging challenges.

    • Erica L. Carpenter
    • Yael P. Mossé
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 9, P: 391-399

  • John Maris and colleagues report results of a genome-wide association and replication study for aggressive neuroblastoma. They show that common variants in the BARD1 locus at 2q35 are strongly associated with the disease.

    • Mario Capasso
    • Marcella Devoto
    • John M Maris
    Research
    Nature Genetics
    Volume: 41, P: 718-723

  • Here, single nucleotide variants within the LMO1 locus are shown to be associated with inherited susceptibility to neuroblastoma, a childhood cancer of the sympathetic nervous system. Acquired structural variation in the same locus was also frequently found in neuroblastoma patients, leading to the suggestion that loci identified through genome-wide association studies might be also prone to somatic alterations and therefore identify potential therapy targets and/or biomarkers of tumour aggressiveness.

    • Kai Wang
    • Sharon J. Diskin
    • John M. Maris
    Research
    Nature
    Volume: 469, P: 216-220

  • A region on chromosome 19p13 is associated with the risk of developing ovarian and breast cancer. Here, the authors genotyped SNPs in this region in thousands of breast and ovarian cancer patients and identified SNPs associated with three genes, which were analysed with functional studies.

    • Kate Lawrenson
    • Siddhartha Kar
    • Simon A. Gayther
    ResearchOpen Access
    Nature Communications
    Volume: 7, P: 1-22

  • ALK is identified as a neuroblastoma predisposition gene. Germline mutations were found in ALK, a tryrosine kinase receptor, in affected families. In addition, somatic point mutations in ALK were found in sporadic cases of neuroblastomas. ALK mutations seem to lead to constitutive activation of its kinase activity and promote cell proliferation.

    • Yaël P. Mossé
    • Marci Laudenslager
    • John M. Maris
    Research
    Nature
    Volume: 455, P: 930-935

  • Copy number variations (CNVs) and single nucleotide polymorphisms (SNPs) are two important potential sources of phenotypic variation in humans; however, only SNPs have been associated with cancer. Here, a CNV at 1q21.1 is shown to be associated with neuroblastoma, and a transcript within this CNV, NBPF23, is implicated in early tumorigenesis of the disease.

    • Sharon J. Diskin
    • Cuiping Hou
    • John M. Maris
    Research
    Nature
    Volume: 459, P: 987-991

  • John Maris, Matthew Meyerson, Marco Marra and colleagues report results of a large-scale sequencing study of neuroblastoma. They observe a low median exonic mutation frequency and strikingly few recurrently mutated genes in these tumors, highlighting challenges for developing targeted therapeutic strategies based on frequently mutated oncogenic drivers.

    • Trevor J Pugh
    • Olena Morozova
    • John M Maris
    Research
    Nature Genetics
    Volume: 45, P: 279-284